Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.
about
Nail Psoriasis: A Review of Treatment OptionsTargeting of interleukin-17 in the treatment of psoriasisSecukinumab.Interleukin-17 in systemic lupus erythematosus: A comprehensive review.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.Secukinumab (AIN-457) for the treatment of Psoriasis.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.Secukinumab in the treatment of psoriasis: an update.The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.
P2860
Q26753038-64AF4B52-7730-45C1-89AC-12D92E765B84Q27026324-81343C86-D102-4D12-B6E6-99698AEEE911Q36391509-E85F7980-E0C0-4237-A0A6-3ED1236D38DCQ38430722-51BADFB3-87EE-4E61-B3D8-CFC23391A783Q38658837-9EFF7859-DD46-4E97-B121-8FBCA169A0A2Q38662868-FF32FC06-73F3-422E-B050-6A0777972876Q38663614-E678AD75-BA22-4935-978B-90CE8C6DE970Q38691418-D311180E-BA10-4A29-8B18-B67EBF4ADB5BQ38840275-1F68A45D-BAA2-4415-B2CF-C1D9FB30607CQ38841466-3CACB053-BF8E-43E1-AE24-954743643CE9Q38856226-BD00ABEB-38DE-4A85-BE56-4E243683BF45Q39096719-CE3F3E29-41BD-440E-9D72-45A699708DE0Q39120166-75A3F2B1-1D36-4761-B616-E2209B14BD40Q46546377-56AFAD76-FF4D-4435-BB6B-ACF36EACF8C4Q47260366-886E625E-8C6B-488F-99B1-5C7292E8DE50Q49985388-C6E72A8F-816C-4DDA-BFDC-56E93CAAE3D0Q51032219-C84BE43E-1575-44CF-9E83-D076D24A761CQ55152453-67C942A3-B059-43CB-AA82-B211DAEC29C0
P2860
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@en
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@nl
type
label
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@en
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@nl
prefLabel
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@en
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial.
@nl
P2093
P2860
P356
P1476
Secukinumab improves hand, foo ...... regimen-finding phase 2 trial
@en
P2093
A B Gottlieb
A Guettner
C Papavassilis
CAIN457A2211 study group
J Nakayama
U Mrowietz
P2860
P304
P356
10.1111/JDV.12359
P50
P577
2014-01-07T00:00:00Z